Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a 1-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, nonprofits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other burdens of trial participants, selecting diverse study sites, including implicit bias training, and taking steps to empower patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2023.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Valbenazine for the treatment of chorea associated with Huntington's disease.
Expert Opin Pharmacother
December 2024
Department of Neurology, UTHealth Houston McGovern Medical School, Houston, TX, USA.
Introduction: Chorea is a motor manifestation of Huntington's disease (HD), which can lead to decreased functional independence and falls. Even though multiple classes of medications have been used to treat this symptom, only the vesicular monoamine transporter 2 (VMAT2) inhibitors tetrabenazine, deutetrabenazine, and valbenazine have been approved by the FDA for this indication.
Areas Covered: This article reviews the pharmacological properties, clinical efficacy, safety, and tolerability of valbenazine in the treatment of chorea in HD.
Improving patient satisfaction based on service quality in clinical trials: A cross-sectional study.
PLoS One
December 2024
College of Nursing, Yonsei University, Seoul, Republic of Korea.
Background: Participants' satisfaction is an important factor in securing competitiveness in clinical trials. In many industries, such as healthcare, customer service quality has been analyzed to increase customer satisfaction. However, no study so far has attempted to measure participants' perceptions of service quality in the clinical trial area and identify its effect on participant satisfaction.
View Article and Find Full Text PDFA randomized controlled trial on anonymizing reviewers to each other in peer review discussions.
PLoS One
December 2024
Machine Learning Department, Carnegie Mellon University, Pittsburgh, Pennsylvania, United States of America.
Many peer-review processes involve reviewers submitting their independent reviews, followed by a discussion between the reviewers of each paper. A common question among policymakers is whether the reviewers of a paper should be anonymous to each other during the discussion. We shed light on this question by conducting a randomized controlled trial at the Conference on Uncertainty in Artificial Intelligence (UAI) 2022 conference where reviewer discussions were conducted over a typed forum.
View Article and Find Full Text PDFApplication of Causal Forest Model to Examine Treatment Effect Heterogeneity in Substance Use Disorder Psychosocial Treatments.
Int J Methods Psychiatr Res
March 2025
Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Objectives: Heterogeneity of treatment effect (HTE) is a concern in substance use disorder (SUD) treatments but has not been rigorously examined. This exploratory study applied a causal forest approach to examine HTE in psychosocial SUD treatments, considering multiple covariates simultaneously.
Methods: Data from 12 randomized controlled trials of nine psychosocial treatments were obtained from the National Institute on Drug Abuse Clinical Trials Network.
Evaluating the safety and effectiveness of α-blockers versus mirabegron for medical expulsive therapy in ureteral calculi: A Systematic review and meta-analysis.
PLoS One
December 2024
Department of Urology, Liaocheng People's Hospital, Liaocheng, China.
Introduction And Aim: The main categories of drugs employed for medical expulsive therapy in patients with ureteral calculi (UC) are alpha-blockers (α-B) and beta-adrenoceptor agonists. This meta-analysis evaluated the safety and effectiveness of α-B versus mirabegron (MIR) in treating UC.
Methods: From January 1980 to October 2024, we extensively searched the Pubmed, Web of science, Cochrane and EMBASE databases to identify randomized controlled trials (RCTs) that compared the effectiveness of α-B and MIR in managing UC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!